| Literature DB >> 26896089 |
Rui Zheng1,2,3, Qian Zhang4, Yidan Guo5, Yue Feng6,7, Li Liu8,9, Amei Zhang10,11, Yue Zhao12,13, Xiaoyu Yang14,15, Xueshan Xia16,17.
Abstract
BACKGROUND: In the past decade, the carbapenemase-producing Enterobacteriaceae (CPE) have been reported worldwide. Emergence of carbapenemase-producing strains among Enterobacteriaceae has been a challenge for treatment of clinical infection. The present study was undertaken to investigate the characteristics of carbapenem-resistant Klebsiella pneumoniae recovered from an outbreak that affected 17 neonatal patients in neonatal intensive care unit (NICU) of Kunming City Maternal and Child health Hospital, which is located in the Kunming city in far southwest of China.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26896089 PMCID: PMC4761218 DOI: 10.1186/s12941-016-0124-6
Source DB: PubMed Journal: Ann Clin Microbiol Antimicrob ISSN: 1476-0711 Impact factor: 3.944
Drug resistance profiles and resistance mechanisms of NDM-1-producing K. pneumoniae
| Strains | Organism | Source |
|
|
|
|
|
|
|
| MICs, μg/mL | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MEM | IPM | CAZ | FOX | AMK | TIG | PIP | PIP/TZB | ATM | LEV | |||||||||||
| M1 | KPN | Sputum |
| – |
|
|
| – | – | – | 128 | 32 | >128 | >128 | 1 | 0.25 | >128 | >128/4 | >128 | <0.06 |
| M2 | KPN | Stool |
| – |
|
| – |
| – |
| 64 | 32 | >128 | >128 | 2 | 0.25 | >128 | >128/4 | 4 | 0.25 |
| M3 | KPN | Stool |
|
|
|
| – | – |
|
| 64 | 16 | >128 | >128 | 1 | 0.25 | >128 | >128/4 | 8 | <0.06 |
| M4 | KPN | Stool |
| – |
|
| – |
|
|
| 128 | 32 | >128 | >128 | 2 | 0.25 | >128 | >128/4 | 4 | <0.06 |
| M5 | KPN | Stool |
|
|
|
| – |
|
|
| 128 | 16 | >128 | >128 | 1 | 0.25 | >128 | >128/4 | 32 | <0.06 |
| M6 | KPN | Stool |
| – |
|
| – | – | – | – | 64 | 16 | >128 | >128 | 2 | 0.25 | >128 | >128/4 | 4 | <0.06 |
| M7 | KPN | Blood |
| – |
|
| – | – | – | – | 64 | 16 | >128 | >128 | 1 | 0.25 | >128 | >128/4 | 8 | 0.25 |
| M8 | KPN | Blood |
|
|
|
| – | – |
| – | 64 | 16 | >128 | >128 | 1 | 0.25 | >128 | >128/4 | 16 | <0.06 |
| M9 | KPN | Sputum |
|
|
|
| – | – |
|
| 64 | 32 | >128 | >128 | 1 | 0.25 | >128 | >128/4 | 8 | <0.06 |
| M10 | KPN | Stool |
| – |
|
| – | – | – | – | 64 | 32 | >128 | >128 | 1 | 0.25 | >128 | >128/4 | 4 | <0.06 |
| M11 | KPN | Stool |
| – |
|
| – | – |
|
| 32 | 4 | >128 | >128 | 1 | 0.5 | >128 | >128/4 | 4 | <0.06 |
| M12 | KPN | Stool |
| – |
|
| – |
|
| – | 64 | 16 | >128 | >128 | 1 | 0.5 | >128 | >128/4 | 64 | <0.06 |
| M13 | KPN | Stool |
| – |
|
| – |
|
| – | 64 | 128 | >128 | >128 | 1 | 1 | >128 | >128/4 | 32 | <0.06 |
| M14 | KPN | Blood |
| – |
|
| – |
| – | – | 64 | 32 | >128 | >128 | 1 | 0.25 | >128 | >128/4 | 16 | <0.06 |
| M15 | KPN | Blood |
| – |
|
| – |
| – | – | 64 | 32 | >128 | >128 | 1 | 0.25 | >128 | >128/4 | 4 | <0.06 |
| M16 | KPN | Stool |
| – |
|
| – |
| – |
| 64 | >128 | >128 | >128 | 8 | 0.5 | >128 | >128/4 | 16 | 8 |
| M17 | KPN | Sputum |
|
|
|
| – |
|
|
| 128 | 16 | >128 | >128 | 1 | 0.5 | >128 | >128/4 | 32 | <0.06 |
| M18 | KPN | Sputum |
|
|
|
| – |
|
|
| 64 | 16 | >128 | >128 | 1 | 0.5 | >128 | >128/4 | 32 | <0.06 |
| M19 | KPN | iw |
|
|
|
| – |
|
|
| 64 | 32 | >128 | >128 | 1 | 0.5 | >128 | >128/4 | 16 | <0.06 |
KPN Klebsiella pneumoniae, ECO Escherichia coli, MEM meropenem, IPM imipenem, CAZ ceftazidime, FOX cefoxitin, AMK amikacin, TIG tigecycline, PIP piperacillin, PIP/TZB piperacillin/tazobactam, ATM aztreonam, LEV levofloxacin, iw incubator water
Fig. 1Dendrogram of PFGE patterns of chromosomal DNA restriction fragments from 19 K. pneumoniae isolates in present study. KPN Klebsiella pneumoniae, iw incubator water
The results of antibiotic susceptibility testing of transconjugants in present study
| Strains | MEM | IPM | CAZ | FOX | AMK | TIG | PIP | PIP/TZP | ATM | LEV |
|---|---|---|---|---|---|---|---|---|---|---|
| M1-J53 | 32 | 4 | 64 | 64 | 1 | <0.125 | >128 | >128/4 | 0.5 | <0.06 |
| M2-J53 | 32 | 4 | 64 | 64 | 1 | <0.125 | >128 | >128/4 | 0.5 | <0.06 |
| M3-J53 | 16 | 4 | 128 | 64 | 1 | <0.125 | >128 | >128/4 | 0.5 | <0.06 |
| M4-J53 | 32 | 16 | 128 | 64 | 1 | <0.125 | >128 | >128/4 | 0.5 | <0.06 |
| M5-J53 | 32 | 4 | 64 | 64 | 1 | <0.125 | >128 | >128/4 | 0.5 | <0.06 |
| M6-J53 | 32 | 4 | 64 | 64 | 1 | <0.125 | >128 | >128/4 | 0.5 | <0.06 |
| M7-J53 | 32 | 8 | 64 | 64 | 1 | <0.125 | >128 | >128/4 | 0.5 | <0.06 |
| M8-J53 | 32 | 4 | 64 | 64 | 1 | <0.125 | >128 | >128/4 | 0.5 | <0.06 |
| M9-J53 | 32 | 4 | 128 | 64 | 1 | <0.125 | >128 | >128/4 | 0.5 | <0.06 |
| M10-J53 | 32 | 4 | 64 | 64 | 1 | <0.125 | >128 | >128/4 | 0.5 | <0.06 |
| M11-J53 | 16 | 4 | >128 | 64 | 1 | <0.125 | >128 | >128/4 | 0.5 | <0.06 |
| M12-J53 | 32 | 8 | 64 | 64 | 1 | <0.125 | >128 | >128/4 | 0.5 | <0.06 |
| M13-J53 | 32 | 4 | 64 | 64 | 1 | <0.125 | >128 | >128/4 | 4 | <0.06 |
| M14-J53 | 32 | 4 | 64 | 64 | 1 | <0.125 | >128 | >128/4 | 2 | <0.06 |
| M15-J53 | 32 | 8 | 64 | 64 | 1 | <0.125 | >128 | >128/4 | 0.5 | <0.06 |
| M16-J53 | 32 | 4 | 64 | 64 | 1 | <0.125 | >128 | >128/4 | 0.5 | <0.06 |
| M17-J53 | 32 | 4 | 32 | 64 | 1 | <0.125 | >128 | >128/4 | 0.5 | <0.06 |
| M18-J53 | 32 | 16 | 64 | 64 | 1 | <0.125 | >128 | >128/4 | 4 | <0.06 |
| M19-J53 | 32 | 4 | 64 | 64 | 1 | <0.125 | >128 | >128/4 | 4 | <0.06 |
|
| <0.125 | <0.125 | <0.125 | 8 | 1 | <0.125 | 4 | 2/4 | 0.5 | <0.06 |
MEM meropenem, IPM imipenem, CAZ ceftazidime, FOX cefoxitin, AMK amikacin, TIG tigecycline, PIP piperacillin, PIP/TZB piperacillin/tazobactam, ATM aztreonam, LEV levofloxacin